Home Angiogenesis Syk inhibitor Fostamatinib (R788)

research use only

Fostamatinib (R788) Syk inhibitor

Cat.No.S2625

Fostamatinib (R788), a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM. It strongly inhibits Syk but not Lyn, and is 5-fold less potent to Flt3. Phase 3.
Fostamatinib (R788) Syk inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 580.46

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Ramos cells Function assay Inhibition of SYK in human Ramos cells, IC50=0.267 μM
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight 580.46 Formula

C23H26FN6O9P

 Storage (From the date of receipt)
CAS No. 901119-35-5 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C

Solubility

In vitro
Batch:

DMSO : 116 mg/mL ( (199.84 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Features
Converted into its active metabolite R406 in vivo.
Targets/IC50/Ki
Syk [1]
41 nM
Adenosine A3 receptor [1]
81 nM
Adenosine transporter [1]
1.84 μM
Monoamine transporter [1]
2.74 μM
In vitro
Fostamatinib (R788) is a prodrug of the spleen tyrosine kinase (Syk) inhibitor R406. It is a competitive inhibitor for ATP binding with a Ki of 30 nM. This compound dose-dependently inhibits anti-IgE-mediated CHMC degranulation with an EC50 of 56 nM. It also inhibits the anti-IgE-induced production and release of LTC4 and cytokines and chemokines, including TNFα, IL-8, and GM-CSF. Inhibition of Syk by R788 results in inhibition of all phosphorylation events downstream of Syk signaling. Next to FcϵRI signaling in CHMC, it most potently inhibits the signaling of IL-4 and IL-2 receptors. It specifically inhibits FcγR signaling in human mast cells, macrophages, and neutrophils. R788 can inhibit local inflammatory injury mediated by immune complexes. [1] It induces apoptosis of the majority of examined DLBCL cell lines. In R788-sensitive DLBCL cell lines, this compound specifically inhibits both tonic- and ligand-induced BCR signaling (autophosphorylation of SYK525/526 and SYK-dependent phosphorylation of the B-cell linker protein [BLNK]). [2]
Kinase Assay
Fluorescence polarization kinase assay and Ki determination
The fluorescence polarization reactions are performed. For Ki determination, duplicate 200-μL reactions are set up at eight different ATP concentrations from 200 μM (2-fold serial dilutions) in the presence of either DMSO or Fostamatinib (R788) at 125, 62.5, 31.25, 15.5, or 7.8 nM. At different time points, 20 μL of each reaction is removed and quenched to stop the reaction. For each concentration of this compound, the rate of reaction at each concentration of ATP is determined and plotted against the ATP concentration to determine the apparent Km and Vmax (maximal rate). Finally the apparent Km (or apparent Ki/Vmax) is plotted against the inhibitor concentration to determine the Ki.
In vivo
Oral administration of Fostamatinib (R788) to mice reduces immune complex-mediated inflammation in a reverse-passive Arthus reaction and two antibody-induced arthritis models. [1] In another study, it effectively inhibits BCR signaling in vivo, resulting in reduced proliferation and survival of the malignant B cells and significantly prolongs survival of the treated animals. [3] This compound also demonstrates a significant reduction in major inflammatory mediators such as TNFalpha, IL-1, IL-6 and IL-18, leading to reduced inflammation and bone degradation in models of rheumatoid arthritis. [4]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05904093 Not yet recruiting
Sickle Cell Disease|Hb-SS Disease|Hemoglobin S|Disease Sickle Cell Anemia|Sickle Cell Disorders|Hemoglobin Beta Thalassemia Disease
National Heart Lung and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)
 May 15 2024 Phase 1
NCT05509582 Enrolling by invitation
Immune Mediated Anemia|Immune Mediated Thrombocytopenia|Chronic GVHD
National Heart Lung and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)
 May 15 2024 Phase 2
NCT06071520 Completed
Primary Immune Thrombocytopenia
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
 March 1 2023 --
NCT05613296 Not yet recruiting
ITP - Immune Thrombocytopenia|Chronic ITP|Refractory ITP
Gruppo Italiano Malattie EMatologiche dell''Adulto
 February 2023 --
NCT04543279 Terminated
Myelofibrosis|Thrombocytopenia
Washington University School of Medicine|Rigel Pharmaceuticals
 May 3 2021 Phase 2
NCT04904276 Terminated
ITP|Immune Thrombocytopenia
Rigel Pharmaceuticals
 May 18 2021 --

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
What’s the difference between S2625 and S2206?

Answer:
It is more stable than S2625. Its water solubility is better than S2625. However, its absorption is harder than S2625, so you need to test the suitable dosage if you use the product in animal assays. The potency of it and S2625 is similar.

Signaling Pathway Map